The U.S. Food and Drug Administration (FDA) on Wednesday removed the need for a positive test for COVID-19 treatments from Pfizer Inc and Merck & Co Inc .
Pfizer's Paxlovid and Merck's Lagevrio pills were given emergency use authorizations in Dec. 2021 for patients with mild-to-moderate COVID who tested positive for the virus, and who were at risk of progressing to severe COVID.
Still, the FDA said the patients should have a current diagnosis of mild-to-moderate COVID infection. The health regulator said individuals with recent known exposure with signs and symptoms may be diagnosed by their healthcare providers with COVID even if they have a negative test result.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer tops profit expectations but gives downbeat outlook, as COVID product sales set to tumbleShares of Pfizer Inc. dropped 2.2% toward a 3 1/2-month low in premarket trading Tuesday, after the drug maker reported fourth-quarter profit that topped...
Read more »
Pfizer forecasts steep fall in 2023 sales of COVID productsPfizer Inc on Tuesday forecast a bigger-than-expected drop in sales of its COVID-19 vaccine and pill in 2023, intensifying investor concerns over demand for the products as governments reduce orders.
Read more »
Pfizer and Moderna quadrupling price of COVID vaccine raises concernsLawmakers from both the U.S. and U.K. have written to the two pharmaceutical companies to express concerns over plans to raise the price of a dose to $110-$130.
Read more »
Pfizer’s COVID revenues have dropped off along with attention to the pandemicWall Street urged Pfizer to lower its COVID revenue estimates. The company did — but it's still betting on higher demand for its vaccine and antiviral by 2025.
Read more »
Pfizer forecasts big drop in revenue after record $100M COVID-led haulChief Executive Albert Bourla said that 2023 should be a “transition year” for Pfizer’s COVID products, before potentially returning to growth in 2024.
Read more »
Pfizer Expects Drop in Revenue as Covid Vaccine Demand WanesThe drugmaker said its revenue would likely drop by as much as a third in 2023 as demand for Covid-19 products reaches a low point and countries adjust to a new phase of managing the virus.
Read more »